Latest News and Press Releases

ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17KPan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of the...

Atavistik Bio today announced the appointment of William Sellers, M.D. to its Scientific Advisory Board.

Atavistik Bio has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics.

Atavistik Bio presents preclinical data on precision oncology development candidate, ATV-1601, a selective allosteric AKT1 E17K small molecule inhibitor.

AKT1 E17K mutation is a clinically validated oncogene that impacts greater than 40,000 cancer patients per year in the United States, with the highest prevalence in breast, endometrial, and prostate...

Atavistik Bio announced today the appointment of oncology clinical development leader Mohammad Hirmand, M.D. to its Board of Directors.

Atavistik Bio, focused on discovering the next generation of precision allosteric therapeutics, announces the appointment of Paul Bruno, Ph.D. as CBO.

Atavistik Bio announced that it has raised an additional $40 million to advance its precision allosteric small molecule therapeutic pipeline.

Mr. Stuart brings more than 25 years of biopharma executive leadership, corporate strategy, and business development experience to guide Atavistik Bio’s advancing discovery pipelineJeff Goater,...

MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and industrialized by Atavistik Bio as the basis of AMPS, is the first...